Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 1/2 4Phase 3 3Phase 4 2Phase 1 2Phase NA 1

Status

Unknown 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Pancreatic Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Lymphoma, T-Cell, Peripheral 2Lymphoma, Extranodal NK-T-Cell 2Biliary Tract Neoplasms 2Thoracic Neoplasms 1Squamous Non-small-cell Lung Cancer 1Oligospermia 1Non-small Cell Lung Cancer Metastatic 1Neoplasms 1Neoplasm Metastasis 1Nasopharyngeal Neoplasms 1Lymphohistiocytosis, Hemophagocytic 1Lung Neoplasms 1Lung Diseases 1Fibrosis 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Adenocarcinoma Pancreas 1Adenocarcinoma 1

Interventions

VAP-cyclo protocol 2Gemcitabine 2apatinib 1N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 1Lenalidomide 1Ifosfamide 1Etoposide 1Dexamethasone 1Cisplatin 1Asparaginase 110-propargyl-10-deazaaminopterin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 4 × Lymphoma, T-Cell, Peripheral × Gemcitabine × Clear all
NCT04040491 2020-05-12

PD-1 Antibody, Chidamide, Lenalidomide and Gemcitabine for Peripheral T-cell Lymphoma

Zhengzhou University

Phase 4 Unknown
100 enrolled
Lymphoid

Lymphoma, T-Cell, Peripheral

NCT03071822 2018-06-11

Combination Chemotherapy Including Cisplatin, Ifosfamide, Gemcitabine, L-asparaginase, Etoposide and Dexamethasone as Treatment of Newly Diagnosed and Relapsed/Refractory Peripheral T Cell Lymphomas

The University of Hong Kong

Phase 4 Unknown
50 enrolled
Lymphoid

Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡